Joseph Tauber is an Ophthalmology physician affiliated with Io Therapeutics. OpenAlex indexes 113 publications with 5,770 citations (h-index 36); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4400 Broadway St
Ste 202
Kansas City, MO 641113342
Telephone
816-531-9100Provider last certified this registry record 28 Mar 2023.
Clinical trials
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Sponsor: Kala Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KOWA COMPANY, LTD.Program year20253 payments$55,318openpaymentsdata.cms.gov ↗
- Bausch & Lomb Americas Inc.Program year20251 payment
- Kowa Research Institute, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
46.6%Prostaglandin Analog26.3%Latanoprost100%Part D≥26 patientsCorticosteroid12%Prednisolone Acetate100%Part D≥14 patients+ 1 more class in this area
Anti-infectives
42.6%Tetracycline-class Drug24.3%Doxycycline Hyclate79%Doxycycline Monohydrate21%Part D<11 patientsMacrolide Antimicrobial18.3%Azithromycin100%Part D≥15 patientsCancer & immunology
6%Calcineurin inhibitor6%Restasis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lirentelimab for severe and chronic forms of allergic conjunctivitis
Journal of Allergy and Clinical Immunology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Dinubile
Io Therapeutics
Michael Zinda, MD
Io Therapeutics
Khushboo Sheth, MB, BS
Io Therapeutics
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”